More harm than good? Potential benefits and unintended consequences associated with screening asymptomatic hospital admissions for severe acute respiratory syndrome coronavirus 2

of

To the Editor-During the coronavirus disease 2019 (COVID-19) pandemic, screening of asymptomatic patients for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the time of healthcare facility admission has often been used in an effort to reduce the risk of nosocomial transmission. [1][2][3] However, the Society for Healthcare Epidemiology of America recently recommended against routine use of asymptomatic screening in healthcare facilities, including admission screening. 4 Such testing is of unclear benefit when other control measures are in place and may result in unintended adverse consequences, including delays in medical care and unnecessary isolation and treatment of noninfectious patients. 4 In Veterans' Affairs (VA) hospitals, it is recommended that all new admissions be screened for SARS-CoV-2 using a polymerase chain reaction (PCR) test. At this stage of the pandemic, PCR screening can be problematic because tests often remain positive for months after COVID-19, and undiagnosed infections are not uncommon. 1,4,5 The cycle threshold (Ct) of the PCR test can be useful in assessing whether asymptomatic patients are infectious because high Ct values, which correlate with low viral burden, suggest a remote infection. 1 In previous studies, many asymptomatic patients with positive PCR tests have been deemed noninfectious based on clinical presentation, serology, and high Ct value. 1,5 Here, we conducted a retrospective study to evaluate the potential benefits and adverse consequences associated with screening asymptomatic patients being admitted to a VA hospital.
The Cleveland VA Medical Center's Research and Development Committee determined that the study was a nonresearch, qualityimprovement project not requiring approval from the institutional review board. Between September 1, 2022, and January 31, 2023, we obtained the Ct values of all patients testing positive for SARS-CoV-2 on admission except those with prior COVID-19 within 90 days. The Xpert Xpress CoV-2 plus assay (Cepheid) was used for testing. Ct values were not provided in the medical record but were available to infectious diseases providers upon request. Medical records and infection control databases were reviewed to obtain information on symptoms, prior COVID-19 diagnosis, test results for COVID-19, treatment and isolation for COVID-19, and suspected transmission based on contact tracing investigations.
Patients were deemed noninfectious if the admission sample and any additional samples collected within 3 days had a Ct value >35, antigen testing (if completed) was negative, and no symptoms consistent with COVID-19 developed during the hospital admission. The Ct cutoff of 35 was chosen based on evidence that positive SARS-CoV-2 cultures, a surrogate for infectiousness, are infrequent for samples with Ct values >35. [6][7][8] The Ct result for the nucleocapsid (N2) target was used; if the N2 target was not detected, the highest Ct value reported for the envelope (E) or RNA-dependent RNA polymerase (RdRP) targets was used.
Our findings are consistent with those of previous studies suggesting that asymptomatic admission screening could be beneficial in reducing nosocomial transmission of SARS-CoV-2. 1-3 Admission screening detected 9 presymptomatic patients and 15 asymptomatic patients with Ct values <35, including 11 with Ct value <30. Such patients may contribute substantially to transmission, including to roommates in healthcare facilities. 9,10 However, it is not clear that universal admission screening adds benefit in settings where multiple control measures are in place, including masking of personnel during patient care. 1 An alternative approach might involve targeted screening of patients being admitted to double-occupancy rooms or to high-risk areas such as oncology wards.
Our findings also highlight the potential for adverse consequences of asymptomatic admission screening using PCR-based assays. 72% of the asymptomatic patients testing positive by PCR were deemed noninfectious based on clinical presentation and Ct values >35. Furthermore, 18% of these patients had prior SARS-CoV-2 infection 4-12 months before admission, probably with persistent positive PCR results. Others likely had undocumented prior infections. Asymptomatic but noninfectious patients experienced a variety of adverse effects, including delays in care and unnecessary isolation and treatment. Although Ct values must be interpreted with caution, [6][7][8]10 our results are consistent with previous reports suggesting that Ct values can be a useful adjunct in evaluation of asymptomatic patients testing positive on admission. 1